These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 17356950)

  • 1. Optimization of hyperthermic intraperitoneal chemotherapy with oxaliplatin plus irinotecan at 43 degrees C after compete cytoreductive surgery: mortality and morbidity in 106 consecutive patients.
    Elias D; Goere D; Blot F; Billard V; Pocard M; Kohneh-Shahri N; Raynard B
    Ann Surg Oncol; 2007 Jun; 14(6):1818-24. PubMed ID: 17356950
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Results of two bi-institutional prospective studies using intraperitoneal oxaliplatin with or without irinotecan during HIPEC after cytoreductive surgery for colorectal carcinomatosis.
    Quenet F; Goéré D; Mehta SS; Roca L; Dumont F; Hessissen M; Saint-Aubert B; Elias D
    Ann Surg; 2011 Aug; 254(2):294-301. PubMed ID: 21772129
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Peritoneal carcinomatosis of colorectal origin.
    Elias D; Raynard B; Farkhondeh F; Goéré D; Rouquie D; Ciuchendea R; Pocard M; Ducreux M
    Gastroenterol Clin Biol; 2006 Oct; 30(10):1200-4. PubMed ID: 17075479
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of the extent and duration of cytoreductive surgery on postoperative hematological toxicity after intraperitoneal chemohyperthermia for peritoneal carcinomatosis.
    Elias D; Raynard B; Boige V; Laplanche A; Estphan G; Malka D; Pocard M
    J Surg Oncol; 2005 Jun; 90(4):220-5. PubMed ID: 15906364
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Heated intra-operative intraperitoneal oxaliplatin plus irinotecan after complete resection of peritoneal carcinomatosis: pharmacokinetics, tissue distribution and tolerance.
    Elias D; Matsuhisa T; Sideris L; Liberale G; Drouard-Troalen L; Raynard B; Pocard M; Puizillou JM; Billard V; Bourget P; Ducreux M
    Ann Oncol; 2004 Oct; 15(10):1558-65. PubMed ID: 15367418
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Complete cytoreductive surgery plus intraperitoneal chemohyperthermia with oxaliplatin for peritoneal carcinomatosis of colorectal origin.
    Elias D; Lefevre JH; Chevalier J; Brouquet A; Marchal F; Classe JM; Ferron G; Guilloit JM; Meeus P; Goéré D; Bonastre J
    J Clin Oncol; 2009 Feb; 27(5):681-5. PubMed ID: 19103728
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bevacizumab doubles the early postoperative complication rate after cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal carcinomatosis of colorectal origin.
    Eveno C; Passot G; Goéré D; Soyer P; Gayat E; Glehen O; Elias D; Pocard M
    Ann Surg Oncol; 2014 Jun; 21(6):1792-800. PubMed ID: 24337648
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The treatment of peritoneal carcinomatosis of colorectal cancer with complete cytoreductive surgery and hyperthermic intraperitoneal peroperative chemotherapy (HIPEC) with oxaliplatin: a Belgian multicentre prospective phase II clinical study.
    Hompes D; D'Hoore A; Van Cutsem E; Fieuws S; Ceelen W; Peeters M; Van der Speeten K; Bertrand C; Legendre H; Kerger J
    Ann Surg Oncol; 2012 Jul; 19(7):2186-94. PubMed ID: 22395983
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Morbidity and mortality of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the management of peritoneal carcinomatosis.
    Spiliotis J; Rogdakis A; Vaxevanidou A; Datsis A; Zacharis G; Christopoulou A
    J BUON; 2009; 14(2):259-64. PubMed ID: 19650176
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oxaliplatin-based versus irinotecan-based hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with peritoneal metastasis from appendiceal and colorectal cancer: a retrospective analysis.
    Glockzin G; Gerken M; Lang SA; Klinkhammer-Schalke M; Piso P; Schlitt HJ
    BMC Cancer; 2014 Nov; 14():807. PubMed ID: 25369730
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and efficacy of hyperthermic intraperitoneal chemoperfusion with high-dose oxaliplatin in patients with peritoneal carcinomatosis.
    Ceelen WP; Peeters M; Houtmeyers P; Breusegem C; De Somer F; Pattyn P
    Ann Surg Oncol; 2008 Feb; 15(2):535-41. PubMed ID: 17960463
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment-related morbidity and toxicity of CRS and oxaliplatin-based HIPEC compared to a mitomycin and doxorubicin-based HIPEC protocol in patients with peritoneal carcinomatosis: a matched-pair analysis.
    Glockzin G; von Breitenbuch P; Schlitt HJ; Piso P
    J Surg Oncol; 2013 May; 107(6):574-8. PubMed ID: 22833286
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy with oxaliplatin for peritoneal carcinomatosis arising from colorectal cancer.
    Gervais MK; Dubé P; McConnell Y; Drolet P; Mitchell A; Sideris L
    J Surg Oncol; 2013 Dec; 108(7):438-43. PubMed ID: 24018983
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of intraperitoneal chemohyperthermia with oxaliplatin in colorectal peritoneal carcinomatosis. Preliminary results in 24 patients.
    Elias D; Sideris L; Pocard M; Edè C; Ben Hassouna D; Ducreux M; Boige V; Côté JF; Lasser P
    Ann Oncol; 2004 May; 15(5):781-5. PubMed ID: 15111347
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neoadjuvant chemotherapy with bevacizumab may improve outcome after cytoreduction and hyperthermic intraperitoneal chemoperfusion (HIPEC) for colorectal carcinomatosis.
    Ceelen W; Van Nieuwenhove Y; Putte DV; Pattyn P
    Ann Surg Oncol; 2014 Sep; 21(9):3023-8. PubMed ID: 24756812
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of two kinds of intraperitoneal chemotherapy following complete cytoreductive surgery of colorectal peritoneal carcinomatosis.
    Elias D; Benizri E; Di Pietrantonio D; Menegon P; Malka D; Raynard B
    Ann Surg Oncol; 2007 Feb; 14(2):509-14. PubMed ID: 17096054
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Perioperative Systemic Therapy vs Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy Alone for Resectable Colorectal Peritoneal Metastases: A Phase 2 Randomized Clinical Trial.
    Rovers KP; Bakkers C; Nienhuijs SW; Burger JWA; Creemers GM; Thijs AMJ; Brandt-Kerkhof ARM; Madsen EVE; van Meerten E; Tuynman JB; Kusters M; Versteeg KS; Aalbers AGJ; Kok NFM; Buffart TE; Wiezer MJ; Boerma D; Los M; de Reuver PR; Bremers AJA; Verheul HMW; Kruijff S; de Groot DJA; Witkamp AJ; van Grevenstein WMU; Koopman M; Nederend J; Lahaye MJ; Kranenburg O; Fijneman RJA; van 't Erve I; Snaebjornsson P; Hemmer PHJ; Dijkgraaf MGW; Punt CJA; Tanis PJ; de Hingh IHJT;
    JAMA Surg; 2021 Aug; 156(8):710-720. PubMed ID: 34009291
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The European contribution to "Sugarbaker's protocol" for the treatment of colorectal peritoneal carcinomatosis.
    Gómez Portilla A; Cendoya I; Olabarría I; Martínez de Lecea C; Gómez Martínez de Lecea C; Gil A; Martín E; Muriel J; Magrach L; Romero E; Lirola A; Guede N; Moraza N; Fernández E; Kvadatze M; Valdovinos M; Larrabide I; Ruiz de Alegría N; Fernández JL; Castillo C; Rua O; Ulibarrena MA
    Rev Esp Enferm Dig; 2009 Feb; 101(2):97-102, 103-6. PubMed ID: 19335045
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Systemic chemotherapy (SC) before cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) in patients with peritoneal mucinous carcinomatosis of appendiceal origin (PMCA).
    Milovanov V; Sardi A; Ledakis P; Aydin N; Nieroda C; Sittig M; Nunez M; Gushchin V
    Eur J Surg Oncol; 2015 May; 41(5):707-12. PubMed ID: 25633641
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Routine second-look after surgical treatment of colonic peritoneal carcinomatosis.
    Delhorme JB; Triki E; Romain B; Meyer N; Rohr S; Brigand C
    J Visc Surg; 2015 Jun; 152(3):149-54. PubMed ID: 25650364
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.